Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, sits down with Nichole Montgomery, Shannon O’Shea, and Phil Sclafani to unpack the sweeping implications of the newly signed One Big Beautiful Bill Act (OBBBA). With nearly a third of the bill dedicated to healthcare, the team explores how this landmark legislation will reshape coverage, funding, and delivery across the payer, provider, and pharma landscape. Discussion highlights: The OBBBA introduces new work requirements and eli...
Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, connects with Nick Donkar, PwC’s U.S. Health Services Deals Leader, and Roel Van den Akker, PwC’s Pharma and Life Sciences Deals Leader, to discuss the 2025 midyear deals outlook across health services and pharma and life sciences. They explore how macroeconomic trends, regulatory pressures, and evolving investment strategies are shaping M&A activity and where new opportunities may emerge as companies look ahead to the second hal...
Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, and Phil Scalfani, PwC’s Pharmaceutical and Life Sciences Consulting Leader, discuss the Trump administration’s executive order on Most Favored Nation (MFN) drug pricing and its far-reaching implications across the healthcare ecosystem. They break down what MFN pricing could mean for pharmaceutical companies, payers, PBMs, and the broader drug supply chain, and share perspectives on how organizations can navigate the uncertainty ahea...
Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, connects with Matt Rich, PwC’s Pharma and Life Sciences R&D Leader, to unpack the recent disruption at the FDA and what it means for the pharmaceutical and biotech sectors. They discuss how companies can stay agile in the face of regulatory uncertainty, avoid preventable delays, and take practical steps to move programs forward with clarity. Discussion highlights: Ongoing restructuring at the FDA is creating uncertainty and delay...
Tune in as Glenn Hunzinger, PwC’s Health Industries Leader and Roel van den Akker, PwC’s Pharma and Life Sciences Deals Leader discuss the rapid rise of China’s biotech industry and what it means for U.S. pharmaceutical companies. They discuss the evolving role of Chinese biotech in the global innovation landscape and share perspectives on how U.S. pharmaceutical companies can thoughtfully assess opportunities, manage cross-border complexities, and build effective partnering and diligence str...
Disclaimer: This episode was recorded on April 11th, 2025, and reflects the information available at the time of recording. As we know, America is in motion here, and so subsequent updates may not be reflected in this discussion as things continue to evolve and change. Tune in as PwC specialists from across the health industry share their insights on how recent policy shifts under the Trump administration could shape healthcare in the years to come. In this episode, Glenn Hunzinger, Jen...
Tune in as PwC's Pharmaceutical & Life Sciences Advisory Leader, Greg Rotz reflects on key market dynamics and explores how pharma leaders can tackle challenges including the $400 billion patent cliff, increasing competition, drug pricing pressures, and transformative disruptions shaping the industry. Discussion highlights: Understanding the scale and implications of the upcoming patent cliff and economic pressures from regulatory changes like the Inflation Reduction ActExamining heighten...
Tune in as PwC specialists discuss the 2025 healthcare outlook, reflecting on 2024’s significant events and exploring how payers and providers can navigate rising costs, scrutiny, AI advances, and policy shifts with resilience and adaptability. Topics include: Medicare and Medicaid drive industry growth amid rising competition, market exits, M&A, AI adoption, and policy challenges.AI's potential to enhance healthcare delivery, improve workforce management, and optimize patient care....
Tune in to listen as PwC’s leaders Roel van den Akker and Nick Donkar provide insights into the 2024 deals landscape and offer a preview of what lies ahead. Topics include: Key topics include: A look back at M&A activity in health industries in 2024The challenges and potential impediments that could affect deal volumes in the coming yearHow artificial intelligence and tech innovations are reshaping the volume and nature of healthcare transactionsKey trends and developments to watch for wi...
Tune in as authors of PwC's U.S. Healthcare Climate Survey discuss key findings and provide insights into understanding healthcare organizations' responses to climate change, the integration of climate strategies, and the challenges faced in implementation. Key topics include: The survey's background, focus, and objectives that address the prioritization of climate strategies by healthcare organizations in response to climate change impactsDifferences in climate strategy approaches across sec...
Tune in as authors of PwC's U.S. Healthcare Consumer Insights and Engagement Survey discuss key findings and provide insights into understanding consumer concerns around healthcare costs, the adoption of tech-enabled healthcare, trust in the healthcare system and how we can take action. Key topics include: The survey's background, focus and objectives that will address ongoing consumer concerns and distrust in the healthcare systemGenerational and financial differences reveal significan...
How can medtech companies drive growth in today's market? Tune in as PwC specialists return to share key insights and strategies to help medtech companies invest in the capabilities required to compete in the future while aiming to exceed near-term expectations for growth and margin improvement. Key topics include: Challenges currently faced by medtech companiesReevaluating business models and new ways to playDriving returns on historical investments in technology by leveraging data and trans...
What can the health industry expect from a second Trump administration? Tune in to hear what executives should watch over the next few months and years to come. Key topics include: President-elect Trump's healthcare agenda and his focus on deregulation, flexibility and choice, and accessibilityPotential implications for medicare, the ACA and IRA drug negotiationsWhat to watch in the first 100 days Speakers: Kelly Griffin, Director, Health Policy and Intelligence Institute Jenny Co...
Tune in as PwC specialists discuss best practices for securing a seat on an emerging company board. Key topics include: Types of emerging companiesResponsibilities of serving on emerging company boardsFive strategies for securing a board positionImportance of industry-specific expertise and continuous learning Speakers: Holly Reeves, Partner, Emerging Company Solutions Market Leader, Health Industries, PwC US Carin Robinson, Director, Governance Insights Center, PwC US Jenny Colap...
Tune in as authors of PwC's 2025 Medical Cost Trend Report: Behind the Numbers, discuss key findings and provide what employers should consider to manage rising healthcare costs. Key points include: Cost projections: The highest medical cost trend in 13 years, with an 8% increase for the group market and 7.5% for the individual marketKey drivers: Inflation, providers' cost-control efforts, increased use of prescription drugs, and new innovative therapiesStrategic adjustments: Employers...
Tune in as PwC specialists discuss how emerging companies (private, pre-IPO) are navigating growth in the health industry. Key topics include: The journey and milestones of emerging companies in the life sciences, biotech and medical technology fields, including capital raising, product development and IPO preparationCommon pitfalls and best practices for managing diverse interests from investors and stakeholdersExamples of how emerging companies are leveraging AI and other technologie...
Tune in as PwC specialists discuss the 2024 outlook for healthcare and how the sector can grow and innovate amid economic challenges and uncertainty. Key Topics include: Major forces impacting the sector: economic pressure, rising costs, labor shortage, and expensive drugsWays to overcome compression and deliver value: industry-wide transformation, tech enabled business model reinvention, transactions and deals to drive transformation, and building trustSpeakers: Laura Robinette,...
Tune in to hear PwC specialists discuss strategies to reinvent the pharma business model and drive growth in the pharmaceutical industry. Key topics include: The headwinds for pharma are real and sustained Rethinking the innovation strategy Accelerate using AI and analytics Lower costs M&A as a catalyst for transformation Protecting the enterpriseSpeakers: Jenny Colapietro, Health Industries Vice Chair, PwC Glenn Hunzinger, Pharmaceutical and Life Sci...
Tune in to hear PwC Deals leaders discuss preparing for deals in 2024, exploring the current state of the deals market and sharing valuable insights from their newly released 2024 deals outlook. Key topics include: Fundamental changes and strategy trends for 2024 and how it’s shaping the health services and pharma landscapesThe role of the regulators and their impact on dealsBusiness model reinvention and the use of new technology to acquire better data and how it’s shaping the deals environm...
Tune in to hear PwC specialists discuss how health ecospheres can provide a transformative model for organizations to collaborate and address large-scale healthcare problems. Topics include: Identifying areas of historical shortcomingsUnderstanding strengths and capabilitiesDetermining the role within the ecosphereSpeakers: Dave Powell, Enterprise Strategy Lead Principal, PwC Tyler Mansfield, Enterprise Strategy Principal, PwC Jenny Colapietro, Health Industries Vice Chair, PwC Igor Bel...